04:06 AM EDT, 05/10/2024 (MT Newswires) -- ADMA Biologics ( ADMA ) reported late Thursday it swung to Q1 net earnings of $0.08 per diluted share from a loss of $0.03 per share a year earlier.

Four analysts polled by Capital IQ expected $0.06 earnings per share.

Revenue for the quarter ended March 31 was $81.9 million, up from $56.9 million a year earlier. Three analysts polled by Capital IQ expected $76.5 million.

For 2024, the company now expects net income of more than $85 million and revenue of more than $355 million, compared with previous guidance of $65 million and $330 million, respectively. Four analysts polled by Capital IQ are expecting revenue of $339.7 million.

Price: 7.74, Change: +0.81, Percent Change: +11.69